Nanoantibodies and Camel Antibodies: Alzheimer’s & Schizophrenia Treatment
- Nanoantibodies,also known as nanobodies,single-domain antibodies,or VHH antibodies,are antibody fragments significantly smaller than traditional antibodies.
- The finding of nanobodies dates back to the early 1990s, when Belgian scientists isolated these previously unkown molecules from camelids (the family of mammals including camels, llamas, and...
- Initial research focused on the therapeutic applications of nanobodies.
“`html
Nanoantibodies: A Potential Revolution in Neurology
Table of Contents
The Promise of Nanoantibodies
Nanoantibodies,also known as nanobodies,single-domain antibodies,or VHH antibodies,are antibody fragments significantly smaller than traditional antibodies. Despite their size, they exhibit remarkable stability and precision in targeting specific molecules. A team of experts from the University of Montpellier and the national Center for Scientific Research (CNR) suggests these nanobodies could pave the way for a new generation of drugs,offering effective and safe treatments for a range of neurodegenerative and neuropsychiatric diseases,including Alzheimer’s and schizophrenia – conditions currently lacking adequate therapeutic options.
The Surprise of the Immune System of Camels
The finding of nanobodies dates back to the early 1990s, when Belgian scientists isolated these previously unkown molecules from camelids (the family of mammals including camels, llamas, and alpacas). These antibody fragments possess two heavy protein chains, characteristic of antibodies, but lack the usual two light chains. This structural difference results in a smaller, lighter molecule capable of selectively binding to a specific antigen, just like a traditional antibody.
Therapeutic Potential and early Challenges
Initial research focused on the therapeutic applications of nanobodies. Though, a significant hurdle emerged: their small size led to rapid elimination by the kidneys after entering the bloodstream. Moreover, crossing the blood-brain barrier – a protective mechanism shielding the brain - proved difficult, frequently enough resulting in the nanobodies being cleared from the body before reaching their intended neuronal targets. Recent research has made substantial progress in overcoming these challenges.
Overcoming the Barriers: Recent Advances
Scientists have developed strategies to enhance the delivery and stability of nanobodies within the brain. these include:
- PEGylation: Attaching polyethylene glycol (PEG) molecules to nanobodies to increase their size and reduce kidney clearance.
- Fusion with carrier Proteins: Linking nanobodies to proteins that can actively transport them across the blood-brain barrier.
- Nanoparticle Encapsulation: Encasing nanobodies within nanoparticles designed for targeted delivery to the brain.
Blood-Brain Barrier Penetration: A Closer Look
the blood-brain barrier (BBB) is a highly selective semipermeable border of endothelial cells that prevents solutes in the circulating blood from non-selectively entering the central nervous system,where delicate neuronal function is maintained. While protective, it presents a major obstacle for drug delivery. Nanobodies, due to their small size and potential for modification, offer a promising avenue for bypassing or exploiting the BBB’s transport mechanisms.
Applications in Neurological Diseases
Nanobodies are being investigated for a wide range of neurological applications: